(±)-BI-D


CAS No. : 1416258-16-6

(±)-BI-D,1416258-16-6
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I001597
Synonyms:2-(tert-butoxy)-2-(4-(chroman-6-yl)-2-methylquinolin-3-yl)acetic acid
Molecular Formula:C25H27NO4
Molecular Weight:405.49
Target:HIV Integrase
IC50:2.4–2.9 μM(HIV-Luc infection of WT and Hdgfrp2 KO cells)
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Purity:  >98%
Cat No:I001597
Cas No:1416258-16-6
Product-Name:(±)-BI-D
SMILES:CC1=NC2=C(C=CC=C2)C(C3=CC4=C(C=C3)OCCC4)=C1C(C(O)=O)OC(C)(C)C

(±)-BI-D is a potent ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site.  Approximately 2.4–2.9 μM of BI-D was required to inhibit 50% of HIV-Luc infection of WT and Hdgfrp2 KO cells, while the IC50 decreased dramatically, to 160–200 nM, in Psip1 and double-KO cells.

1. Nucleic Acids Res. 2012 Dec;40(22):11518-30. doi: 10.1093/nar/gks913. Epub 2012 Oct 5.
HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor.
Wang H(1), Jurado KA, Wu X, Shun MC, Li X, Ferris AL, Smith SJ, Patel PA, Fuchs JR, Cherepanov P, Kvaratskhelia M, Hughes SH, Engelman A.
Author information:
(1)Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
The binding of integrase (IN) to lens epithelium-derived growth factor (LEDGF)/p75 in large part determines the efficiency and specificity of HIV-1 integration. However, a significant residual preference for integration into active genes persists in Psip1 (the gene that encodes for LEDGF/p75) knockout (KO) cells. One other cellular protein, HRP2, harbors both the PWWP and IN-binding domains that are important for LEDGF/p75 co-factor function. To assess the role of HRP2 in HIV-1 integration, cells generated from Hdgfrp2 (the gene that encodes for HRP2) and Psip1/Hdgfrp2 KO mice were infected alongside matched control cells. HRP2 depleted cells supported normal infection, while disruption of Hdgfrp2 in Psip1 KO cells yielded additional defects in the efficiency and specificity of integration. These deficits were largely restored by ectopic expression of either LEDGF/p75 or HRP2. The double-KO cells nevertheless supported residual integration into genes, indicating that IN and/or other host factors contribute to integration specificity in the absence of LEDGF/p75 and HRP2. Psip1 KO significantly increased the potency of an allosteric inhibitor that binds the LEDGF/p75 binding site on IN, a result that was not significantly altered by Hdgfrp2 disruption. These findings help to rule out the host factor-IN interactions as the primary antiviral targets of LEDGF/p75-binding site IN inhibitors.
Related Products
  • CAS No. :544467-07-4
    Product Name:

    HIV-1 integrase inhibitor

    Cat No: I004001 View details
  • CAS No. :871038-72-1
    Product Name:

    Raltegravir potassium

    Cat No: I008974 View details
  • CAS No. :697761-98-1
    Product Name:

    Elvitegravir

    Cat No: A000301 View details
  • CAS No. :159989-64-7
    Product Name:

    Nelfinavir

    Cat No: I002032 View details